Venture Capital Investors

Abingworth

VC investing group Abingworth provides capital to promising tech companies.

Venture Investor Overview

Venture Investor
Abingworth
Status
Active
Investor Type
Venture Capital
Activity Level
100 transactions
Funds Raised
At least $795 million
Industry Focus
AdTech
Biopharmaceutical
Healthcare Services

Contact Information

Contact
Stephen Bunting
Title
Managing Partner
Mailing Address
3000 Sand Hill Road B1 - 145
Menlo Park, CA 94025
USA
Phone
(650) 926-0600
Website
www.abingworth.com
Email Address
Not Recorded

Background Information

Overview
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies
Profile
Abingworth LinkedIn Company Profile
Social Media
Abingworth Company Twitter Account
Company News
Abingworth News
Facebook
Abingworth on Facebook
YouTube
Abingworth on YouTube
Last Transaction
3/25/2024

Transaction History

Our records indicate that Abingworth invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Q32 Bio
3/25/2024
$42,000,000
Iambic Therapeutics
10/6/2023
$100,000,000
Ascend Gene & Cell Therapies
5/9/2023
$132,500,000
Pathalys Pharma
1/18/2023
$150,000,000
Escient Pharmaceuticals
11/28/2022
$120,000,000
HilleVax
9/9/2021
$135,000,000
Glycomine
6/24/2021
$68,000,000
Adaptate Biotherapeutics
4/19/2021
$18,000,000
Vera Therapeutics
1/22/2021
$80,000,000
Scorpion Therapeutics
1/8/2021
$162,000,000
Atsena Therapeutics
12/17/2020
$55,000,000
Reneo Pharmaceuticals
12/10/2020
$95,000,000
Scorpion Therapeutics
10/27/2020
$108,000,000
Q32 Bio
5/29/2020
$46,000,000
SutroVax
3/27/2020
$110,000,000
Spruce Biosciences
2/21/2020
$88,000,000
Jasper Therapeutics
12/10/2019
$35,000,000
IFM Therapeutics
12/3/2019
$55,500,000
Phathom Pharmaceuticals
5/16/2019
$140,000,000
Gynesonics
1/4/2019
$75,000,000
IFM Therapeutics
7/21/2018
$4,000,000
SutroVax
6/8/2018
$85,000,000
Attenua
5/1/2018
$35,000,000
VenatoRx Pharmaceuticals
7/26/2017
$42,000,000
eFFECTOR Therapeutics
7/25/2017
$38,600,000
SutroVax
3/22/2017
$64,000,000
IFM Therapeutics
6/23/2016
$27,000,000
Tizona Therapeutics
3/8/2016
$43,000,000
Kesios Therapeutics
12/3/2015
$28,420,000
SutroVax
7/24/2015
$22,000,000
Gynesonics
7/22/2015
$43,000,000
CRISPR Therapeutics
4/30/2015
$64,000,000
Chiasma
2/27/2015
$70,000,000
Personalis
1/13/2015
$33,000,000
eFFECTOR Therapeutics
9/30/2014
$4,180,000
Proteon Therapeutics
5/16/2014
$45,000,000
Wilson Therapeutics
4/17/2014
$40,000,000
Personalis
10/7/2013
$22,000,000
Labcyte
9/30/2013
$501,900
Dicerna Pharmaceuticals
8/1/2013
$60,000,000
eFFECTOR Therapeutics
5/21/2013
$45,000,000
Avedro
3/6/2013
$43,000,000
Gynesonics
2/20/2013
$21,000,000
Chiasma
7/24/2012
$38,500,000
Sonitus Medical
5/15/2012
$25,000,000
Sientra
3/29/2012
$65,000,000
Personalis
9/30/2011
$5,007,000
Valeritas Holdings
9/12/2011
$150,000,000
MD On-Line
6/30/2011
$12,000,000
Pathwork Diagnostics
10/6/2010
$30,000,000
Dicerna Pharmaceuticals
8/11/2010
$25,000,000
Secure EDI
5/5/2010
$40,000,000
Clovis Oncology
12/31/2009
$65,635,000
Zogenix
9/23/2009
$51,000,000
PrimeraDx
9/21/2009
$20,000,000
Avila Therapeutics
7/27/2009
$30,000,000
Clovis Oncology
6/30/2009
$146,300,000
SFJ Pharmaceuticals
3/16/2009
$45,000,000
Hydra Biosciences
1/16/2009
$22,000,000
Valeritas Holdings
12/31/2008
$9,999,800
Valeritas Holdings
9/30/2008
$39,999,700
Pathwork Diagnostics
9/5/2008
$20,000,000
Labcyte
3/31/2008
$3,808,800
Hydra Biosciences
3/13/2008
$17,016,100
Zogenix
1/9/2008
$18,000,000
PrimeraDx
1/8/2008
$21,000,000
Broncus Medical
12/31/2007
$12,400,000
Hydra Biosciences
12/31/2007
$16,983,900
Fovea Pharmaceuticals
12/13/2007
$44,000,000
Avila Therapeutics
8/20/2007
Unknown
Portola Pharmaceuticals
5/7/2007
$70,000,000
ConxCys
3/31/2007
$9,986,000
Gynesonics
1/25/2007
$16,500,000
Synosia Therapeutics
1/5/2007
$32,500,000
Iconic Therapeutics
12/31/2006
$6,000,000
Magellan Biosciences
11/28/2006
$50,000,000
Broncus Medical
9/30/2006
$29,500,000
Ablynx
8/23/2006
$50,000,000
Synosia Therapeutics
6/30/2006
$30,000,100
NeoRx
4/27/2006
$65,000,000
Chroma Therapeutics
4/3/2006
$53,000,000
Synosia Therapeutics
3/31/2006
$2,499,900
Superfeedr
2/23/2006
$45,000,000
Guava Technologies
11/29/2005
$7,000,000
Portola Pharmaceuticals
11/8/2005
$46,000,000
Fovea Pharmaceuticals
11/7/2005
$25,000,000
Senseonics
11/2/2005
$30,000,000
Adiana
8/25/2005
$23,000,000
Labcyte
7/25/2005
$21,000,000
Oxagen Limited
5/23/2005
$59,800,000
Entelos
3/31/2005
$5,040,000
Solexa
9/27/2004
$14,400,000
Chroma Therapeutics
6/14/2004
$18,914,200
PowderJect Pharmaceuticals PLC
5/17/2004
$34,500,000
Ablynx
4/6/2004
$30,000,000
Hydra Biosciences
1/12/2004
$18,875,000
Guava Technologies
12/18/2003
$27,000,000
Portola Pharmaceuticals
12/8/2003
$21,000,000
Xenogen
7/10/2003
$22,000,000
Epigenomics AG
4/3/2003
$22,500,000

 

Investor Contacts

Title
Name
Email & Social
Partner
Joseph Anderson
  Joseph Anderson LinkedIn Profile  Joseph Anderson Twitter Account  Joseph Anderson News  Joseph Anderson on Facebook
Partner
Michael Bigham
  Michael Bigham LinkedIn Profile  Michael Bigham Twitter Account  Michael Bigham News  Michael Bigham on Facebook
Managing Partner
Stephen Bunting
  Stephen Bunting LinkedIn Profile  Stephen Bunting Twitter Account  Stephen Bunting News  Stephen Bunting on Facebook
Partner
Shelley Chu
  Shelley Chu LinkedIn Profile  Shelley Chu Twitter Account  Shelley Chu News  Shelley Chu on Facebook
Principal
Michelle Doig
  Michelle Doig LinkedIn Profile  Michelle Doig Twitter Account  Michelle Doig News  Michelle Doig on Facebook
Partner
Brian Gallagher
  Brian Gallagher LinkedIn Profile  Brian Gallagher Twitter Account  Brian Gallagher News  Brian Gallagher on Facebook
Partner
Ken Haas
  Ken Haas LinkedIn Profile  Ken Haas Twitter Account  Ken Haas News  Ken Haas on Facebook
Partner
Timothy Haines
  Timothy Haines LinkedIn Profile  Timothy Haines Twitter Account  Timothy Haines News  Timothy Haines on Facebook
Partner
Vincent Miles
  Vincent Miles LinkedIn Profile  Vincent Miles Twitter Account  Vincent Miles News  Vincent Miles on Facebook
Principal
John Shields
  John Shields LinkedIn Profile  John Shields Twitter Account  John Shields News  John Shields on Facebook
Partner
Kurt von Emster
  Kurt von Emster LinkedIn Profile  Kurt von Emster Twitter Account  Kurt von Emster News  Kurt von Emster on Facebook

 

Funds

Our database includes the following fund closing(s) for Abingworth. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Abingworth Bioventures VII
7/9/2018
$315,000,000
Abingworth Clinical Co-Development Fund
1/21/2016
$105,000,000
Abingworth Bioventures VI
10/9/2013
$375,000,000

 

Portfolio Companies

Abingworth has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Ablynx
Adaptate Biotherapeutics
Adiana
Ascend Gene & Cell Therapies
Atsena Therapeutics
Attenua
Avedro
Avila Therapeutics
Broncus Medical
Chiasma
Chroma Therapeutics
Clovis Oncology
ConxCys
CRISPR Therapeutics
Dicerna Pharmaceuticals
eFFECTOR Therapeutics
Entelos
Epigenomics AG
Escient Pharmaceuticals
Fovea Pharmaceuticals
Glycomine
Guava Technologies
Gynesonics
HilleVax
Hydra Biosciences
Iambic Therapeutics
Iconic Therapeutics
IFM Therapeutics
Jasper Therapeutics
Kesios Therapeutics
Labcyte
Magellan Biosciences
MD On-Line
NeoRx
Oxagen Limited
Pathalys Pharma
Pathwork Diagnostics
Personalis
Phathom Pharmaceuticals
Portola Pharmaceuticals
PowderJect Pharmaceuticals PLC
PrimeraDx
Proteon Therapeutics
Q32 Bio
Reneo Pharmaceuticals
Scorpion Therapeutics
Secure EDI
Senseonics
SFJ Pharmaceuticals
Sientra
Solexa
Sonitus Medical
Spruce Biosciences
Superfeedr
SutroVax
Synosia Therapeutics
Tizona Therapeutics
Valeritas Holdings
VenatoRx Pharmaceuticals
Vera Therapeutics
Wilson Therapeutics
Xenogen
Zogenix

 

 

 

 

Browse more venture capital investors:

Abies Ventures | Able Partners

 

Share this article

 

About Our Venture Capital Investor Database

Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.